NewAmsterdam Pharma N.V. Quarterly Income Statement
NASDAQ: NAMSHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
NewAmsterdam Pharma N.V. revenue and earnings
In the quarter ended Jun 30, 2026, NewAmsterdam Pharma N.V. generated $3.7 million in revenue, down 80.7% from the same quarter a year earlier. NewAmsterdam Pharma N.V. reported a net loss of $64.1 million, compared with a loss of $17.4 million a year earlier. Operating margin was -1752.6%.
Diluted earnings per share came in at -$0.52.
Summary generated from market data by MetaCap's automated system. Methodology
NewAmsterdam Pharma N.V. income statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3.70M | 3.04M | 32.00K | 348.00K | 19.14M | 2.98M | 12.77M | 29.11M | 2.28M | 1.40M | 803.00K | 2.94M |
| Revenue growth (YoY) | -80.67% | +2.08% | -99.75% | -98.80% | +740.06% | +112.56% | +1490.54% | +889.83% | +32.73% | -83.76% | — | — |
| Operating Expenses | 68.56M | 61.46M | 66.01M | 55.49M | 54.78M | 71.90M | 56.00M | 54.11M | 54.85M | 56.88M | 51.88M | 52.50M |
| Research & Development | 41.67M | 38.01M | 38.59M | 30.97M | 27.52M | 44.75M | 34.90M | 35.70M | 38.38M | 42.43M | 41.29M | 43.37M |
| Selling, General & Admin | 26.89M | 23.45M | 27.42M | 24.52M | 27.26M | 27.15M | 21.11M | 18.41M | 16.48M | 14.45M | 10.59M | 9.13M |
| Operating Income | -64.86M | -58.42M | -65.98M | -55.14M | -35.63M | -68.92M | -43.23M | -25.00M | -52.58M | -55.48M | -51.07M | -49.56M |
| Pretax Income | -64.14M | -48.44M | -74.92M | -72.00M | -17.36M | -39.53M | -92.18M | -16.65M | -39.01M | -93.77M | -49.47M | -47.13M |
| Income Tax | — | — | — | — | — | — | 0 | -1.00K | — | — | — | — |
| Net Income | -64.14M | -48.44M | -74.92M | -72.00M | -17.36M | -39.53M | -92.18M | -16.65M | -39.01M | -93.77M | -49.49M | -47.13M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — | — | — |
| EPS (Basic) | -0.52 | -0.40 | -0.62 | -0.61 | -0.15 | -0.34 | -0.91 | -0.18 | -0.41 | -1.06 | -0.60 | -0.57 |
| EPS (Diluted) | -0.52 | -0.40 | -0.62 | -0.61 | -0.15 | -0.34 | -0.91 | -0.18 | -0.41 | -1.06 | -0.60 | -0.57 |
| Shares Outstanding (Basic) | 123.37M | 121.72M | — | 119.00M | 118.56M | 116.12M | — | 94.75M | 94.71M | 88.38M | — | 82.47M |
| Shares Outstanding (Diluted) | 123.37M | 121.72M | — | 119.00M | 118.56M | 116.12M | — | 94.75M | 94.71M | 88.38M | — | 82.47M |
| EBITDA | -64.81M | -58.36M | -65.92M | -55.08M | -35.59M | -68.87M | -43.18M | -24.98M | -52.56M | -55.47M | -51.06M | -49.54M |
| Operating Margin | -1752.61% | -1921.71% | -206187.50% | -15845.69% | -186.13% | -2314.47% | -338.47% | -85.89% | -2306.93% | -3960.17% | -6360.40% | -1685.07% |
| Net Margin | -1732.91% | -1593.45% | -234134.37% | -20691.09% | -90.70% | -1327.30% | -721.71% | -57.18% | -1711.58% | -6692.86% | -6163.76% | -1602.62% |
This table shows 12 quarterly periods of NewAmsterdam Pharma N.V.'s income statement, from Q2 2026 back to Q3 2023, across 15 line items including revenue, operating expenses, research & development. Values in USD; B = billions, M = millions. Fiscal periods follow NAMS's reporting calendar. What is a income statement?